Daniel E. Stone Discloses 12.96% Stake in Scinai Immunotherapeutics

Ticker: SCNI · Form: SC 13G/A · Filed: 2024-01-24T00:00:00.000Z

Sentiment: bullish

Topics: insider-ownership, beneficial-ownership, biotech, amendment

TL;DR

**Daniel E. Stone owns 12.96% of Scinai Immunotherapeutics, a big individual bet.**

AI Summary

Daniel E. Stone, an individual investor, has filed an Amendment No. 2 to Schedule 13G, reporting a beneficial ownership of 624,000 Ordinary ADS Shares in Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) as of December 31, 2023. This represents a significant 12.96% stake in the company, based on 4,814,425 shares outstanding as of January 15, 2024. This substantial ownership by a single individual could signal strong conviction in Scinai's future, potentially influencing investor sentiment and stock performance.

Why It Matters

A large individual ownership stake like this can indicate a strong belief in the company's prospects, potentially attracting other investors and influencing the stock's perceived value.

Risk Assessment

Risk Level: low — This filing indicates a significant ownership stake by an individual, which is generally not a direct risk but rather an indicator of investor confidence.

Analyst Insight

Investors should note Daniel E. Stone's substantial 12.96% stake in Scinai Immunotherapeutics Ltd. as of December 31, 2023. This could be a positive signal, suggesting a knowledgeable investor sees value. Further research into Daniel E. Stone's investment history and Scinai's recent developments would be prudent.

Key Numbers

624,000 — Shares owned by Daniel E. Stone (Represents his sole voting and dispositive power in Scinai Immunotherapeutics Ltd.)
12.96% — Percentage of class owned (Indicates a significant individual stake in Scinai Immunotherapeutics Ltd.)
4,814,425 — Total outstanding shares (The denominator used to calculate Daniel E. Stone's percentage ownership as of January 15, 2024.)

Key Players & Entities

Daniel E. Stone (person) — Reporting person and beneficial owner of shares
Scinai Immunotherapeutics Ltd. (company) — The issuer of the securities
BiondVax Pharmaceuticals Ltd. (company) — Former name of Scinai Immunotherapeutics Ltd.
624,000 (dollar_amount) — Number of shares beneficially owned by Daniel E. Stone
12.96% (dollar_amount) — Percentage of class represented by Daniel E. Stone's ownership
4,814,425 (dollar_amount) — Total issued and outstanding shares of the Issuer as of January 15, 2024
December 31, 2023 (date) — Date of event which requires filing of this statement
January 15, 2024 (date) — Date used to calculate outstanding shares for percentage ownership

Forward-Looking Statements

The significant individual ownership by Daniel E. Stone could lead to increased investor confidence in Scinai Immunotherapeutics Ltd. (Scinai Immunotherapeutics Ltd.) — medium confidence, target: Within the next 6-12 months

FAQ

Who is the reporting person in this SC 13G/A filing?

The reporting person is Daniel E. Stone, an individual investor, as stated in Item 1 of the filing.

What is the name of the issuer whose securities are being reported?

The issuer is Scinai Immunotherapeutics Ltd., formerly known as BiondVax Pharmaceuticals Ltd., as identified in the 'Name of Issuer' section and the subject company data.

How many shares does Daniel E. Stone beneficially own in Scinai Immunotherapeutics Ltd.?

Daniel E. Stone beneficially owns 624,000 Ordinary ADS Shares, as reported in Row 9 of the filing.

What percentage of the class of securities does Daniel E. Stone's ownership represent?

Daniel E. Stone's ownership represents 12.96% of the class, based on 4,814,425 issued and outstanding shares as of January 15, 2024, as stated in Row 11 and its footnote.

What was the date of the event that required this filing?

The date of the event which required this filing was December 31, 2023, as specified in the 'Date of Event Which Requires Filing of This Statement' section.

From the Filing

0000912282-24-000070.txt : 20240124 0000912282-24-000070.hdr.sgml : 20240124 20240124143359 ACCESSION NUMBER: 0000912282-24-000070 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240124 DATE AS OF CHANGE: 20240124 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-89384 FILM NUMBER: 24555972 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: STONE DANIEL E. CENTRAL INDEX KEY: 0001948744 ORGANIZATION NAME: FILING VALUES: FORM TYPE: SC 13G/A MAIL ADDRESS: STREET 1: 1200 BRICKELL AVENUE, #1470 CITY: MIAMI STATE: FL ZIP: 33131 SC 13G/A 1 sc13a2.htm AMENDMENT NO. 2 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   Amendment No. 2 to SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 SCINAI IMMUNOTHERAPEUTCS LTD. (formerly BiondVax Pharmaceuticals Ltd.) (Name of Issuer) Ordinary ADS Shares (Title of Class of Securities) 09073Q204 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the Appropriate box to designate the rule pursuant to which this schedule is filed:          Rule 13d-1(b) X  Rule 13d-1(c)       Rule 13d-1(d) 1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS     DANIEL E. STONE 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   (a) (b)         3 SEC USE ONLY         4 CITIZENSHIP OR PLACE OF ORGANIZATION   United States   5 SOLE VOTING POWER NUMBER OF   624,000 SHARES 6 SHARED VOTING POWER BENEFICIALLY   0 OWNED BY 7 SOLE DISPOSITIVE POWER EACH   624,000 REPORTING 8 SHARED DISPOSITIVE POWER PERSON WITH   0 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   624,000 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*   q         11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9   12.96%* *Based on 4,814,425 issued and outstanding shares of the Issuer as of January 15, 2024. 12 TYPE OF REPORTING PERSON*   IN *SEE INSTRUCTIONS BEFORE FILLING OUT! Item 1 (a). Name of Issuer: Scinai Immunotherapeutics Ltd., formerly BiondVax Pharmaceuticals Ltd. (the “Issuer”) Item 1 (b). Address of Issuer’s Principal Executive Offices: Jerusalem Biopark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem L3 00000 Item 2 (a). Name of Person Filing: Daniel E. Stone Item 2 (b). Address of Principal Business Office or, if None, Residence: 1200 Brickell Avenue, #1470 Miami, FL 33131 Item 2 (c). Citizenship: United States Item 2 (d). Title of Class of Securities: Ordinary ADS Shares Item 2   (e). CUSIP Number: 09073Q204 Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under Section 15 of the Act; (b) Bank as defined in Section 3(a)(6) of the Act; (c) Insurance Company as defined in Section 3(a)(19) of the Act; (d) Investment Company registered under Section 8 of the Investment Company Act; (e) Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E)